Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Complement C5 Inhibitors & C5 Receptor Antagonists" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence ...
A research team at the Medical University of South Carolina reports in Cells that the complement system, part of the body's natural immune defenses, is a key driver of inflammatory responses that ...
The FDA has approved AstraZeneca’s danicopan (Voydeya) as add-on therapy to C5-targeted antibodies for extravascular haemolysis (EVH) in adults with paroxysmal nocturnal haemoglobinuria (PNH).
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) presented data from its OMS906 program yesterday at the 4 th Complement-based Drug Development Summit. OMS906 is the company’s lead human ...
An MUSC research team reports in Cells that the complement system, part of the body’s natural immune defenses, is a key driver of inflammatory responses that contribute to fetal brain inflammation and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results